Literature DB >> 29562148

Hazards of Hazard Ratios - Deviations from Model Assumptions in Immunotherapy.

Brian M Alexander1, Jonathan D Schoenfeld1, Lorenzo Trippa1.   

Abstract

Mesh：

Year:  2018        PMID： 29562148     DOI： 10.1056/NEJMc1716612

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  18 in total

Review 1.  Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC.

Authors:  Niki Karachaliou; Manuel Fernandez-Bruno; Jillian Wilhelmina Paulina Bracht; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2018-12

2.  Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?

Authors:  Niki Karachaliou; Manuel Fernandez-Bruno; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2018-09

3.  Is more the better?-cetuximab in non-small cell lung cancer patients.

Authors:  Teresa Moran
Journal:  Transl Lung Cancer Res       Date:  2018-09

4.  In Pursuit of Evidence in Air Pollution Epidemiology: The Role of Causally Driven Data Science.

Authors:  Marco Carone; Francesca Dominici; Lianne Sheppard
Journal:  Epidemiology       Date:  2020-01       Impact factor: 4.822

5.  Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies.

Authors:  Zachary R McCaw; Lu Tian; Jiawei Wei; Brian Lee Claggett; Frank Bretz; Garrett Fitzmaurice; Lee-Jen Wei
Journal:  Stat Med       Date:  2021-12-10       Impact factor: 2.373

6.  Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer.

Authors:  Guodong Zhang; Qing Xu; Xiangyun Zhang; Moran Yang; Yiying Wang; Mengdi He; Jiaqi Lu; Haiou Liu
Journal:  Cancer Med       Date:  2021-05-05       Impact factor: 4.452

7.  Seamless phase I/II design for novel anticancer agents with competing disease progression.

Authors:  Lucie Biard; Shing M Lee; Bin Cheng
Journal:  Stat Med       Date:  2021-07-02       Impact factor: 2.497

8.  Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective.

Authors:  Casey Quinn; Louis P Garrison; Anja K Pownell; Michael B Atkins; Gérard de Pouvourville; Kevin Harrington; Paolo Antonio Ascierto; Phil McEwan; Samuel Wagner; John Borrill; Elise Wu
Journal:  J Immunother Cancer       Date:  2020-07       Impact factor: 13.751

9.  The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors.

Authors:  Daniel E Meyers; Igor Stukalin; Isabelle A Vallerand; Ryan T Lewinson; Aleksi Suo; Michelle Dean; Scott North; Aliyah Pabani; Tina Cheng; Daniel Y C Heng; D Gwyn Bebb; Don G Morris
Journal:  Cancers (Basel)       Date:  2019-11-02       Impact factor: 6.639

Review 10.  Master protocols in immuno-oncology: do novel drugs deserve novel designs?

Authors:  Luca Mazzarella; Stefania Morganti; Antonio Marra; Dario Trapani; Giulia Tini; Piergiuseppe Pelicci; Giuseppe Curigliano
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.